Top

Inflammation Research

Published in:

01-03-2014 | Original Research Paper

Opioid signaling in mast cells regulates injury responses associated with heterotopic ossification

Authors: Lixin Kan, Amelia A. Mutso, Tammy L. McGuire, Apkar Vania Apkarian, John A. Kessler

Published in: Inflammation Research | Issue 3/2014

Abstract

Introduction

Previous studies found that neuron specific enolase promoter (Nse-BMP4) transgenic mice have increased expression of the nociceptive mediator, substance P and exaggerated local injury responses associated with heterotopic ossification (HO). It is of interest great to know the pain responses in these mice and how the opioid signaling is involved in the downstream events such as mast cell (MC) activation.

Materials and methods

This study utilized a transgenic mouse model of HO in which BMP4 is expressed under the control of the Nse-BMP4. The tactile sensitivity and the cold sensitivity of the mice were measured in a classic inflammatory pain model (carrageenan solution injected into the plantar surface of the left hind paw). The MC activation and the expression profiles of different components in the opioid signaling were demonstrated through routine histology and immunohistochemistry and Western blotting, in the superficial and deep muscle injury models.

Results

We found that the pain responses in these mice were paradoxically attenuated or unchanged, and we also found increased expression of both Methionine Enkephalin (Met-Enk), and the μ-opioid receptor (MOR). Met-Enk and MOR both co-localized within activated MCs in limb tissues. Further, Nse-BMP4;MOR^−/− double mutant mice showed attenuated MC activation and had a significant reduction in HO formation in response to injuries.

Conclusions

These observations suggest that opioid signaling may play a key role in MC activation and the downstream inflammatory responses associated with HO. In addition to providing insight into the role of MC activation and associated injury responses in HO, these findings suggest opioid signaling as a potential therapeutic target in HO and possibly others disorders involving MC activation.

Available only for authorised users

Ramalho LS, Oliveira LF, Cavellani CL, Ferraz ML, de Oliveira FA, Miranda Correa RR, et al. Role of mast cell chymase and tryptase in the progression of atherosclerosis: study in 44 autopsied cases. Ann Diagn Pathol. 2013;17(1):28–31. doi:10.1016/j.anndiagpath.2012.04.007.PubMedCrossRef

Huang P, Liu D, Gan X, Zhang R, Gao W, Xia Z, et al. Mast cells activation contribute to small intestinal ischemia reperfusion induced acute lung injury in rats. Injury. 2012;43(8):1250–6. doi:10.1016/j.injury.2011.12.027.PubMedCrossRef

Costanza M, Colombo MP, Pedotti R. Mast cells in the pathogenesis of multiple sclerosis and experimental autoimmune encephalomyelitis. Int J Mol Sci. 2012;13(11):15107–25. doi:10.3390/ijms131115107.PubMedCentralPubMedCrossRef

Lv J, Huang Y, Zhu S, Yang G, Zhang Y, Leng J, et al. MCP-1-induced histamine release from mast cells is associated with development of interstitial cystitis/bladder pain syndrome in rat models. Mediators Inflamm. 2012;2012:358184. doi:10.1155/2012/358184.PubMedCentralPubMed

Moalem G, Tracey DJ. Immune and inflammatory mechanisms in neuropathic pain. Brain Res Rev. 2006;51(2):240–64. doi:10.1016/j.brainresrev.2005.11.004.PubMedCrossRef

Theoharides TC, Angelidou A, Alysandratos KD, Zhang B, Asadi S, Francis K, et al. Mast cell activation and autism. Biochim Biophys Acta. 2012;1822(1):34–41. doi:10.1016/j.bbadis.2010.12.017.PubMedCrossRef

Niemi K, Baumann MH, Kovanen PT, Eklund KK. Serum amyloid A (SAA) activates human mast cells which leads into degradation of SAA and generation of an amyloidogenic SAA fragment. Biochim Biophys Acta. 2006;1762(4):424–30. doi:10.1016/j.bbadis.2006.01.001.PubMedCrossRef

Anand P, Singh B, Jaggi AS, Singh N. Mast cells: an expanding pathophysiological role from allergy to other disorders. Naunyn Schmiedebergs Arch Pharmacol. 2012;385(7):657–70. doi:10.1007/s00210-012-0757-8.PubMedCrossRef

Kan L, Lounev VY, Pignolo RJ, Duan L, Liu Y, Stock SR, et al. Substance P signaling mediates BMP-dependent heterotopic ossification. J Cell Biochem. 2011;112(10):2759–72. doi:10.1002/jcb.23259.PubMedCentralPubMedCrossRef

10.

Gannon FH, Glaser D, Caron R, Thompson LD, Shore EM, Kaplan FS. Mast cell involvement in fibrodysplasia ossificans progressiva. Hum Pathol. 2001;32(8):842–8. doi:10.1053/hupa.2001.26464.PubMedCrossRef

11.

Kumar V, Sharma A. Mast cells: emerging sentinel innate immune cells with diverse role in immunity. Mol Immunol. 2010;48(1–3):14–25. doi:10.1016/j.molimm.2010.07.009.PubMedCrossRef

12.

Brooks J, Tracey I. From nociception to pain perception: imaging the spinal and supraspinal pathways. J Anat. 2005;207(1):19–33. doi:10.1111/j.1469-7580.2005.00428.x.PubMedCrossRef

13.

De Felipe C, Herrero JF, O’Brien JA, Palmer JA, Doyle CA, Smith AJ, et al. Altered nociception, analgesia and aggression in mice lacking the receptor for substance P. Nature. 1998;392(6674):394–7. doi:10.1038/32904.PubMedCrossRef

14.

Cao YQ, Mantyh PW, Carlson EJ, Gillespie AM, Epstein CJ, Basbaum AI. Primary afferent tachykinins are required to experience moderate to intense pain. Nature. 1998;392(6674):390–4. doi:10.1038/32897.PubMedCrossRef

15.

Al-Hasani R, Bruchas MR. Molecular mechanisms of opioid receptor-dependent signaling and behavior. Anesthesiology. 2011;115(6):1363–81. doi:10.1097/ALN.0b013e318238bba6.PubMedCentralPubMed

16.

Ossipov MH, Dussor GO, Porreca F. Central modulation of pain. J Clin Invest. 2010;120(11):3779–87. doi:10.1172/JCI43766.PubMedCentralPubMedCrossRef

17.

Ren K, Dubner R. Interactions between the immune and nervous systems in pain. Nat Med. 2010;16(11):1267–76. doi:10.1038/nm.2234.PubMedCentralPubMedCrossRef

18.

Tramullas M, Lantero A, Diaz A, Morchon N, Merino D, Villar A, et al. BAMBI (bone morphogenetic protein and activin membrane-bound inhibitor) reveals the involvement of the transforming growth factor-beta family in pain modulation. J Neurosci. 2010;30(4):1502–11. doi:10.1523/JNEUROSCI.2584-09.2010.PubMedCrossRef

19.

Kitterman JA, Strober JB, Kan L, Rocke DM, Cali A, Peeper J, et al. Neurological symptoms in individuals with fibrodysplasia ossificans progressiva. J Neurol. 2012;259(12):2636–43. doi:10.1007/s00415-012-6562-y.

20.

Chaplan SR, Bach FW, Pogrel JW, Chung JM, Yaksh TL. Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods. 1994;53(1):55–63.PubMedCrossRef

21.

Choi Y, Yoon YW, Na HS, Kim SH, Chung JM. Behavioral signs of ongoing pain and cold allodynia in a rat model of neuropathic pain. Pain. 1994;59(3):369–76.PubMedCrossRef

22.

Rocha AC, Fernandes ES, Quintao NL, Campos MM, Calixto JB. Relevance of tumour necrosis factor-alpha for the inflammatory and nociceptive responses evoked by carrageenan in the mouse paw. Br J Pharmacol. 2006;148(5):688–95. doi:10.1038/sj.bjp.0706775.PubMedCrossRef

23.

Langsdorf EF, Mao X, Chang SL. A role for reactive oxygen species in endotoxin-induced elevation of MOR expression in the nervous and immune systems. J Neuroimmunol. 2011;236(1–2):57–64. doi:10.1016/j.jneuroim.2011.05.009.PubMedCentralPubMedCrossRef

24.

Assis MA, Collino C, Figuerola Mde L, Sotomayor C, Cancela LM. Amphetamine triggers an increase in met-enkephalin simultaneously in brain areas and immune cells. J Neuroimmunol. 2006;178(1–2):62–75. doi:10.1016/j.jneuroim.2006.05.009.PubMedCrossRef

25.

Huang J, Xu J, Pang S, Bai B, Yan B. Age-related decrease of the LAMP-2 gene expression in human leukocytes. Clin Biochem. 2012;45(15):1229–32. doi:10.1016/j.clinbiochem.2012.06.016.PubMedCrossRef

26.

Kuehn HS, Gilfillan AM. G protein-coupled receptors and the modification of FcepsilonRI-mediated mast cell activation. Immunol Lett. 2007;113(2):59–69. doi:10.1016/j.imlet.2007.08.007.PubMedCentralPubMedCrossRef

27.

Klinker JF, Seifert R. Morphine and muscle relaxants are receptor-independent G-protein activators and cromolyn is an inhibitor of stimulated G-protein activity. Inflamm Res. 1997;46(2):46–50.PubMedCrossRef

28.

Blunk JA, Schmelz M, Zeck S, Skov P, Likar R, Koppert W. Opioid-induced mast cell activation and vascular responses is not mediated by mu-opioid receptors: an in vivo microdialysis study in human skin. Anesth Analg. 2004;98(2):364–70 table of contents.PubMedCrossRef

29.

Poonawala T, Levay-Young BK, Hebbel RP, Gupta K. Opioids heal ischemic wounds in the rat. Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair. Wound Repair Regen. 2005;13(2):165–74. doi:10.1111/j.1067-1927.2005.130207.x.PubMedCrossRef

30.

Rook JM, McCarson KE. Delay of cutaneous wound closure by morphine via local blockade of peripheral tachykinin release. Biochem Pharmacol. 2007;74(5):752–7. doi:10.1016/j.bcp.2007.06.005.PubMedCentralPubMedCrossRef

31.

Cao T, Grant AD, Gerard NP, Brain SD. Lack of a significant effect of deletion of the tachykinin neurokinin-1 receptor on wound healing in mouse skin. Neuroscience. 2001;108(4):695–700.PubMedCrossRef

32.

Ruck P, Horny HP, Kaiserling E. Immunoreactivity of human tissue mast cells: nonspecific binding of primary antibodies against regulatory peptides by ionic linkage. J Histochem Cytochem. 1990;38(6):859–67.PubMedCrossRef

33.

Liu YQ, Qiu F, Qiu CY, Cai Q, Zou P, Wu H, et al. Cannabinoids inhibit acid-sensing ion channel currents in rat dorsal root ganglion neurons. PLOS One. 2012;7(9):e45531. doi:10.1371/journal.pone.0045531.PubMedCentralPubMedCrossRef

34.

Lin CC, Chen WN, Chen CJ, Lin YW, Zimmer A, Chen CC. An antinociceptive role for substance P in acid-induced chronic muscle pain. Proc Natl Acad Sci USA. 2012;109(2):E76–83. doi:10.1073/pnas.1108903108.PubMedCrossRef

Title: Opioid signaling in mast cells regulates injury responses associated with heterotopic ossification
Authors: Lixin Kan
Amelia A. Mutso
Tammy L. McGuire
Apkar Vania Apkarian
John A. Kessler
Publication date: 01-03-2014
Publisher: Springer Basel
Published in: Inflammation Research / Issue 3/2014
Print ISSN: 1023-3830
Electronic ISSN: 1420-908X
DOI: https://doi.org/10.1007/s00011-013-0690-4

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Introduction

Materials and methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2014

Histamine induces chemotaxis and phagocytosis in murine bone marrow-derived macrophages and RAW 264.7 macrophage-like cells via histamine H4-receptor

Effects of costimulation on intrahepatic immunopathogenesis in patients with chronic HBV infection

CX3CL1 (fractalkine) and TNFα production by perfused human placental lobules under normoxic and hypoxic conditions in vitro: the importance of CX3CR1 signaling

Anti-inflammatory effects of rutin on HMGB1-induced inflammatory responses in vitro and in vivo

The antagonistic effect of the sigma 1 receptor ligand (+)-MR200 on persistent pain induced by inflammation

Wheal and flare reactions in skin prick tests of patients treated with montelukast alone or in combination with antihistamines

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials